Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide Effervescent Tablets vs Suspension in EoE
NCT02280616Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jun 2011
- Primary completion
- Apr 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EPI-EE in eosinophilic esophagitis (EoE) (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoints: Rate of histological remission at 2 weeks and Change in the mean numbers of eos at 2 weeks. Started Jun 2011; status: completed.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT02280616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280616.